Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 2/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21111698 | 1.00 | RORC (0.34) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL21111722 | 0.88 | — | — | |
| SCHEMBL21111724 | 0.88 | — | — | |
| SCHEMBL2256948 | 0.81 | NR1H2 (0.40) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL23538445 | 0.79 | RORC (0.37) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL21158214 | 0.79 | NR1H2 (0.37) | RORCNR1H2PDK4 | |
| SCHEMBL16422844 | 0.78 | STS (0.35) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL19168628 | 0.78 | RORC (0.38) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL5809590 | 0.76 | RORC (0.37) | RORCNR1H2HTR6STSPDK4 | |
| SCHEMBL19176058 | 0.75 | RORC (0.35) | RORCNR1H2HTR6STSPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20190209550-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209550-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | SAMHD1, AZI2, CDKN1A | RORC 1375/4885NR1H2 4005/4885HTR6 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.